Cognition Therapeutics (CGTX) Accumulated Depreciation & Amortization (2020 - 2025)
Cognition Therapeutics (CGTX) reported Accumulated Depreciation & Amortization of $187000.0 for Q4 2025, down 83.82% year-over-year from $1.2 million in Q4 2024, and down 83.82% on a QoQ basis from $1.2 million in Q4 2024.
Cognition Therapeutics (CGTX) has 6 years of Accumulated Depreciation & Amortization data on file, last reported at $187000.0 in Q4 2025.
- Quarterly Accumulated Depreciation & Amortization fell 83.82% year-over-year to $187000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $187000.0 (down 83.82% YoY) and the FY2025 annual result came in at $187000.0, down 83.82% from the prior year.
- Accumulated Depreciation & Amortization fell to $187000.0 in Q4 2025 per CGTX's latest filing, from $1.2 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $1.2 million in Q4 2024 and bottomed at $187000.0 in Q4 2025.
- The 5-year median for Accumulated Depreciation & Amortization is $953000.0 (2022), against an average of $843000.0.
- The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization increased 11.97%; it then tumbled 83.82% in 2025.
- Tracing CGTX's Accumulated Depreciation & Amortization over 5 years: stood at $870000.0 in 2021, then climbed by 9.54% to $953000.0 in 2022, then grew by 10.07% to $1.0 million in 2023, then climbed by 10.2% to $1.2 million in 2024, then plunged by 83.82% to $187000.0 in 2025.
- Per Business Quant, the three latest CGTX Accumulated Depreciation & Amortization figures stand at $187000.0 (Q4 2025), $1.2 million (Q4 2024), and $1.0 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 187,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Dec 31, 2024 | 1.16 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 953,000.00 |
| Dec 31, 2022 | 953,000.00 |
| Dec 31, 2021 | 870,000.00 |
| Dec 31, 2021 | 870,000.00 |
| Dec 31, 2020 | 777,000.00 |
| Dec 31, 2020 | 777,000.00 |